DIAGNOS Announces a Three-Year Contract Renewal with Optina Diagnostics Providing a Telemedicine Platform to Support their Early Detection of Alzheimer’s Disease Test
September 02 2021 - 9:00AM
DIAGNOS Inc. (“
DIAGNOS” or “the
Company”) (TSX Venture: ADK) (OTCQB: DGNOF) (FRA:
4D4A), a leader in early detection of certain critical health
issues, announces today a contract renewal to provide its
telemedicine platform based on CARA (Computer Assisted Retina
Analysis) to Optina Diagnostics (“Optina”) for an additional
three-year period. Optina uses DIAGNOS’ Cloud platform to upload
images generated by the Optina-4CTM hyperspectral camera to be used
with their awAIrTM Cerebral Amyloid Status test (for Research Use
Only).
Using the DIAGNOS CARA Cloud platform, the
Optina’s proprietary retinal images are processed, securely stored,
and available to be shared and reviewed by healthcare professionals
and clinics in various locations around the world. Optina benefits
from the high throughput of the DIAGNOS CARA Cloud platform as well
as the ease of use of the teleophthalmology platform currently used
by doctors and other medical professionals.
“This contract renewal is a testimony of the
high quality of our telemedicine platform and the agility of
DIAGNOS people to adapt its platform to enable the rich data
collected with the unique Optina-4CTM hyperspectral camera. We are
proud to contribute to the success of innovative companies like
Optina. Their work towards a precise Alzheimer’s diagnosis is a
service we all wish for our loved ones,” said Yves-Stephane
Couture, Vice-President of Sales at DIAGNOS.
“By working with DIAGNOS, Optina will continue
benefiting from rapid data exchange with eye clinics and
physicians. This is a key element to support the development of our
Retinal Deep PhenotypingTM diagnostic platform that enables the
creation of new tests,” said David Lapointe, President and
CEO of Optina.
Optina Diagnostics is a privately held company.
For commercial reasons the value of the contract will remain
confidential.
About Optina DiagnosticsOptina
Diagnostics is a Montreal-based company focused on changing
mindsets when it comes to Brain Health and systemic diseases. With
a first application in the early diagnosis of Alzheimer’s, Optina
challenges the status quo by providing an accurate, simple, and
non-invasive optical test to understand the age-related sources of
memory loss, empowering millions.
Additional information about Optina is available
at www.optinadx.com.
About DIAGNOSDIAGNOS is a
publicly traded Canadian corporation dedicated to early detection
of critical health problems based on its FLAIRE Artificial
Intelligence (AI) platform. FLAIRE allows for quick modifying and
developing of applications such as CARA (Computer Assisted Retina
Analysis). CARA’s image enhancement algorithms provide sharper,
clearer and easier-to-analyze retinal images. CARA is a
cost-effective tool for real-time screening of large volumes of
patients. CARA has been cleared for commercialization by the
following regulators: Health Canada, the FDA (USA), CE (Europe),
COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).
Additional information is available
at www.diagnos.com and www.sedar.com.
For further information, please contact:
Mr. André Larente, PresidentDIAGNOS Inc.Tel:
450-678-8882 ext. 224Email: alarente@diagnos.ca
Corporate Communications:Nancy MassicotteIR Pro
Communications Inc.Dir: +1 604-507-3377TF: 1-866-503-3377Email:
nancy@irprocommunications.com
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publicly update or revise any forward-looking information, whether
as a result of new information, future events or otherwise. The
forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024